Home Cart Sign in  
Chemical Structure| 251945-92-3 Chemical Structure| 251945-92-3

Structure of Derenofylline
CAS No.: 251945-92-3

Chemical Structure| 251945-92-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Derenofylline (SLV 320) is a potent, selective and orally active adenosine A1 receptor antagonist, with Ki values of 1 nM, 200 nM and 398 nM for human A1, A3 and A2A receptors respectively. Derenofylline suppresses cardiac fibrosis and attenuates albuminuria without affecting blood pressure in rats[1].

Synonyms: Slv 320

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Derenofylline

CAS No. :251945-92-3
Formula : C18H20N4O
M.W : 308.38
SMILES Code : O[C@H]1CC[C@H](NC2=C3C(NC=C3)=NC(C4=CC=CC=C4)=N2)CC1
Synonyms :
Slv 320
MDL No. :MFCD12756289
InChI Key :RBZNJGHIKXAKQE-UHFFFAOYSA-N
Pubchem ID :9953065

Safety of Derenofylline

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Derenofylline

GPCR

Isoform Comparison

Biological Activity

Description
Derenofylline (SLV 320) is a potent, selective, and orally active adenosine A1 receptor antagonist, with Ki values of 1 nM, 200 nM, and 398 nM for human A1, A3, and A2A receptors, respectively. Derenofylline mitigates cardiac fibrosis and reduces albuminuria in rats without affecting blood pressure [1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00568009 - Terminated(additional enrolmen... More >>t criteria made patients' recruitment not feasible anymore) Less << November 2008 -
NCT00160134 Congestive Heart Failure Phase 2 Completed - Germany ... More >> Site 1 Bad Nauheim, Germany Less <<
NCT00744341 Acute Decompensated Heart Fail... More >>ure; Renal Dysfunction Less << Phase 2 Terminated(This study was stop... More >>ped 29OCT2009 due to strategic drug development considerations) Less << - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.24mL

0.65mL

0.32mL

16.21mL

3.24mL

1.62mL

32.43mL

6.49mL

3.24mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories